Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S 055746 in AML or High-Risk MDS
NCT02920541Phase 1Completed
- Sponsor
- Servier
- Start
- Jan 2015
- Primary completion
- May 2018
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of S55746 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Servier. Primary endpoints: Maximum Tolerated Dose and Incidence of Adverse Events. Started Jan 2015; status: completed.
02
Drugs
S55746
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02920541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920541.